Menu
Create an Account
Log in
Home
Activities
Courses and Conferences
HIV In-Person and Virtual Courses
Earn CME From On-Demand Webcasts
The 2022 Ryan White HIV/AIDS Program CLINICAL CONFERENCE
Conference on Retroviruses and Opportunistic Infections
About IAS–USA Courses
Webinars
Upcoming Webinars
2023 On-Demand Webinars
Earn CME From On-Demand Webinars
About Webinars
COVID-19 Dialogue Series
Upcoming Dialogues
On-Demand Dialogues
Topics in Antiviral Medicine
Current Issues
Previous Issues
TAM
Policies and Practices
Resources
Guidelines
HIV Drug Resistance Mutations
Podcasts
On-Demand Webcasts
Slides
Research Collaboration
Useful Resources for COVID-19 Information and Guidance
Practice Question of the Week
Fellow/Student Resources
Permission Request Form
Other Resources
About
Mission
IAS–USA Scientific Leadership Board
IAS–USA Governance
Core Faculty
Staff
CME
Funding Information
Careers
Donate
Website Policies
FAQs
Contact
Topics in Antiviral Medicine
™
October/November 2021
Volume 29, Issue 4
Download here
, or select individual articles
Claim CME
Invited Reviews
Challenges and Opportunities for Preexposure Prophylaxis
Mary Catherine Cambou, MD, Raphael J. Landovitz, MD, MSc
HIV and Cardiovascular Disease: From Insights to Interventions
Matthew J. Feinstein, MD, MSc
Perspective
Primary Care Concerns for the Aging Population With HIV
Steven C. Johnson, MD
Topics in Antiviral Medicine™
Current Issues
Previous Issues
TAM
Policies and Practices
TAM
Author and Contributor Guidelines
Topics in Antiviral Medicine
Editorial Board
Home
Activities
Courses and Conferences
HIV In-Person and Virtual Courses
Earn CME From On-Demand Webcasts
The 2022 Ryan White HIV/AIDS Program CLINICAL CONFERENCE
Conference on Retroviruses and Opportunistic Infections
About IAS–USA Courses
Webinars
Upcoming Webinars
2023 On-Demand Webinars
Earn CME From On-Demand Webinars
About Webinars
COVID-19 Dialogue Series
Upcoming Dialogues
On-Demand Dialogues
Topics in Antiviral Medicine
Current Issues
Previous Issues
TAM
Policies and Practices
Resources
Guidelines
HIV Drug Resistance Mutations
Podcasts
On-Demand Webcasts
Slides
Research Collaboration
Useful Resources for COVID-19 Information and Guidance
Practice Question of the Week
Fellow/Student Resources
Permission Request Form
Other Resources
About
Mission
IAS–USA Scientific Leadership Board
IAS–USA Governance
Core Faculty
Staff
CME
Funding Information
Careers
Donate
Website Policies
FAQs
Contact
Practice Question of the Week
March 20, 2023: Platform Trial Designs
Which of the following statements regarding platform trials is true?
A. They have been commonly used for decades, with more than 100 trials conducted pre-COVID-19
B. They are larger than a combination of individually randomized clinical trials (RCTs) answering the same questions.
D. Sites may have the option to include or exclude participants for each treatment based on product availability
D. Sites may have the option to include or exclude participants for each treatment based on product availability
E. To maintain the blinding, only agents with the same mode of administration (eg, oral, intravenous) can be combined into a single platform trial
View CROI Website
View Related Sources
Leave Feedback
Subscribe
CLOSE